Elsevier,
Engineering Applications of Artificial Intelligence, Volume 123, August 2023
Using brain tissue from donors with Alzheimer's disease, Anderson et al. identify new links between gene regulation and disease. These regulators could represent future clinical targets or disease markers for Alzheimer's diagnosis and treatment.
Elsevier,
Free Radical Biology and Medicine, Volume 204, 1 August 2023
In vivo triple transgenic AD mouse model brains and retinas showed hypoxic vessels expressing hypoxyprobe and HIF-1α. In in vitro OGD-treated endothelial cells, HIF-1α upregulated NADPH oxidase (NOX) (i.e., Nox2, Nox4). NLRP1 protein was promoted by OGD, and such effect was blocked by downregulation of Nox4 and HIF-1α. Hypoxic endothelial cells of AD brains and retinas markedly expressed NLRP1, ASC, caspase-1, and interleukin-1β (IL-1β). Chronic hypoxia in microvascular endothelial cells leads to HIF-1α-NLRP1 circuit in AD.
Press Release
RELX SDG Inspiration Day 2023: Fostering Global Cooperation to Advance Biodiversity
The event saw spirited discussions on how leaders, businesses, organisations, and people can help protect nature and biodiversity.
Over 1500 people gathered virtually on 13 June 2023 for the ninth RELX SDG Inspiration Day: "Not Too Late for Nature: Biodiversity and the UN Sustainable Development Goals."
Elsevier,
The Lancet HIV, 2023, ISSN 2352-3018, https://doi.org/10.1016/S2352-3018(23)00106-6.
This paper reviews the unique perspective that Indigenous People have on the HIV/AIDS epidemic, and the interactions between Indigenous Identities and HIV. The authors call for a human rights based approach to ending the HIV epidemic among Indigenous Peoples.
In a first-of-its-kind report, learn which companies are the world’s leading patent owners with the potential to drive transformative innovation toward the United Nations Sustainable Development Goals (SDGs).
Elsevier,
The Lancet Gastroenterology and Hepatology, Volume 8, July 2023
This Article supports SDG 3 by analysing peripartum antiviral prophylaxis for hepatitis B in 110 countries, finding that it could be beneficial in averting both neonatal hepatitis B infections and DALYS, and that it might be cost-effective depending on how it is implemented and the associated diagnostic costs.
